Biotech News
Related news
MNKDMannKind2026-07-28 20:01 EST
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
ALTAltimmune2026-08-05 12:00 EST
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
CVRXCVRx2026-07-23 20:30 EST
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
ALTAltimmune2026-05-06 11:30 EST
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
CVRXCVRx2026-04-27 20:30 EST
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
BLTEBelite Bio2026-08-13 01:45 EST
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
ALGSAligos Therapeutics2026-08-06 12:00 EST
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
MLYSMineralys Therapeutics2026-08-04 12:00 EST
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
RYTMRhythm Pharmaceuticals2026-08-04 11:01 EST
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-07-29 10:30 EST
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKDMannKind2026-07-28 20:01 EST
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MNKDMannKind2026-07-24 10:35 EST
MannKind Announces $50 Million Private Placement
MNKDMannKind2026-07-24 10:30 EST
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
Stock data
- Close
- 4.15 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States